NFA
IONS icon

Nuveen Fund Advisors’s Ionis Pharmaceuticals IONS Stock Holding History

Nuveen Fund Advisors’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-4,282
Closed -$205K – 454
2016
Q4 		$205K Buy
+4,282
New +$169K 0.03% 422

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Nuveen Fund Advisors's IONS Position: Q1 2017 in Review

Nuveen Fund Advisors sold out of Ionis Pharmaceuticals (IONS) in Q1 2017, closing a stake of 4,282 shares — an estimated $205K sold.

Nuveen Fund Advisors first reported a position in IONS in Q4 2016 and held it in 1 quarter. The position peaked at $205K in Q4 2016. 270 funds tracked by Wall St. Rank hold IONS as of Q1 2017.

  • Nuveen Fund Advisors reported no remaining Ionis Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Nuveen Fund Advisors sold 4,282 Ionis Pharmaceuticals shares in Q1 2017, an estimated $205K.
  • Nuveen Fund Advisors first reported a position in Ionis Pharmaceuticals in Q4 2016 and held it in 1 quarter.
  • Nuveen Fund Advisors's Ionis Pharmaceuticals position peaked at $205K in Q4 2016.
  • 270 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2017.

Based on Nuveen Fund Advisors's 13F filing for Q1 2017, filed 15 May 2017.